Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

Related Articles by Review for PubMed (Select 19436038)

1.

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO.

J Natl Cancer Inst. 2009 May 20;101(10):736-50. doi: 10.1093/jnci/djp082. Epub 2009 May 12.

2.

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, Van de Vijver M, Viale G, Loi S, Reis-Filho JS.

Ann Oncol. 2012 Dec;23(12):2997-3006. doi: 10.1093/annonc/mds586. Review.

3.

Promise and failure of targeted therapy in breast cancer.

Giordano A, Tagliabue E, Pupa SM.

Front Biosci (Schol Ed). 2012 Jan 1;4:356-74. Review.

PMID:
22202065
4.

The changing role of pathology in breast cancer diagnosis and treatment.

Leong AS, Zhuang Z.

Pathobiology. 2011;78(2):99-114. doi: 10.1159/000292644. Epub 2011 Jun 14. Review.

5.

Ki67 and proliferation in breast cancer.

Pathmanathan N, Balleine RL.

J Clin Pathol. 2013 Jun;66(6):512-6. doi: 10.1136/jclinpath-2012-201085. Epub 2013 Feb 22. Review.

PMID:
23436927
6.

[Gene expression analysis in breast cancer. A new diagnostic tool in pathology].

Denkert C.

Pathologe. 2013 Sep;34(5):413-8. doi: 10.1007/s00292-013-1781-2. Review. German.

PMID:
23934410
7.

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.

Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C, Piccart M.

J Clin Oncol. 2014 Sep 1;32(25):2794-803. doi: 10.1200/JCO.2013.54.1870. Epub 2014 Jul 21. Review.

PMID:
25049332
8.

[Translational research and diagnostics for breast cancer].

Kreipe HH.

Pathologe. 2012 Nov;33 Suppl 2:282-90. doi: 10.1007/s00292-012-1645-1. Review. German.

PMID:
23064514
9.

Luminal-B breast cancer and novel therapeutic targets.

Tran B, Bedard PL.

Breast Cancer Res. 2011;13(6):221. doi: 10.1186/bcr2904. Epub 2011 Nov 30. Review.

10.

Tailoring adjuvant treatments for the individual patient with luminal breast cancer.

Munzone E, Curigliano G, Colleoni M.

Hematol Oncol Clin North Am. 2013 Aug;27(4):703-14, vii-viii. doi: 10.1016/j.hoc.2013.05.012. Epub 2013 Jun 18. Review.

PMID:
23915740
11.

Basal phenotype breast cancer: implications for treatment and prognosis.

Pazaiti A, Fentiman IS.

Womens Health (Lond Engl). 2011 Mar;7(2):181-202. doi: 10.2217/whe.11.5. Review.

PMID:
21410345
12.

Correlation between Ki67 and breast cancer prognosis.

Kontzoglou K, Palla V, Karaolanis G, Karaiskos I, Alexiou I, Pateras I, Konstantoudakis K, Stamatakos M.

Oncology. 2013;84(4):219-25. doi: 10.1159/000346475. Epub 2013 Jan 24. Review.

PMID:
23364275
13.

[Genomic diagnosis in breast cancer practice].

Masuda S.

Rinsho Byori. 2012 Oct;60(10):969-74. Review. Japanese.

PMID:
23323462
14.

Nonfamilial breast cancer subtypes.

Ringnér M, Staaf J, Jönsson G.

Methods Mol Biol. 2013;973:279-95. doi: 10.1007/978-1-62703-281-0_18. Review.

PMID:
23412797
15.

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.

Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM.

Oncologist. 2013;18(2):123-33. doi: 10.1634/theoncologist.2012-0397. Epub 2013 Feb 12. Review.

16.

Gene expression profiling in breast cancer: classification, prognostication, and prediction.

Reis-Filho JS, Pusztai L.

Lancet. 2011 Nov 19;378(9805):1812-23. doi: 10.1016/S0140-6736(11)61539-0. Review.

PMID:
22098854
17.

Does microenvironment contribute to the etiology of estrogen receptor-negative breast cancer?

Barcellos-Hoff MH.

Clin Cancer Res. 2013 Feb 1;19(3):541-8. doi: 10.1158/1078-0432.CCR-12-2241. Epub 2013 Jan 16. Review.

18.

Ki67 in breast cancer: prognostic and predictive potential.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA.

Lancet Oncol. 2010 Feb;11(2):174-83. doi: 10.1016/S1470-2045(09)70262-1. Review.

PMID:
20152769
19.

[Molecular taxonomy of luminal breast cancer in 2015].

Franchet C, Duprez-Paumier R, Lacroix-Triki M.

Bull Cancer. 2015 Jun;102(6 Suppl 1):S34-46. doi: 10.1016/S0007-4551(15)31216-9. Review. German.

PMID:
26118875
20.

Ki67--no evidence for its use in node-positive breast cancer.

Andre F, Arnedos M, Goubar A, Ghouadni A, Delaloge S.

Nat Rev Clin Oncol. 2015 May;12(5):296-301. doi: 10.1038/nrclinonc.2015.46. Epub 2015 Mar 17. Review.

PMID:
25781576
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk